What type of study is this?

This is a In Vitro Study study.

What question did this study set out to answer?

This research explores menin inhibition as a potential treatment for myeloproliferative neoplasms (MPNs).

December 8, 2025Blood

View Full Paper

Ask AI

Bookmark

Authors

Experimental treatment reduces megakaryocyte cell lines and leukocyte counts in human myeloproliferative neoplasms, suggesting menin may be a target.

This research explores menin inhibition as a potential treatment for myeloproliferative neoplasms (MPNs).
Investigated effects of revumenib on megakaryocyte progenitor cells using human CD34+ cells in vitro.
Conducted single-cell RNA sequencing to analyze the impact of revumenib on hematopoietic lineages.
Used CRISPR-Cas9 to knockout MEN1 in human CD34+ cells to confirm data from revumenib treatment.
Assessed revumenib's effects in murine MPN models including MPLW515L and JAK2V617F variants.
Revumenib significantly decreased megakaryocyte progenitor cells and mature megakaryocyte numbers.
Monotherapy with revumenib lowered leukocyte and platelet counts in MPN models.
Combination with ruxolitinib enhanced suppression of leukocytosis and normalized spleen weight.
Revumenib improved overall survival and was well tolerated in mice.

Hall et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Experimental treatment reduces megakaryocyte cell lines and leukocyte counts in human myeloproliferative neoplasms, suggesting menin may be a target.